Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Pulmocide has raised $52.0M in total funding. The most recent round was Series C. The last funding was announced in December 2022.
Pulmocide's investors include Vivo Capital, Longwood Fund, Jeito Capital, SR One, SV Health Investors.
Pulmocide is headquartered in London, United Kingdom.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Pulmocide is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pulmocide — Funding & Investors." VCBacked, December 6, 2022, https://www.vcbacked.co/company/pulmocide. Accessed October 30, 2026.
VCBacked. (2022). Pulmocide — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/pulmocide
{{cite web |title=Pulmocide — Funding & Investors |url=https://www.vcbacked.co/company/pulmocide |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated